(INMD) InMode - NASDAQ
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 812m USD | Total Return: 0.5% in 12m
Avg Turnover: 9.47M
EPS Trend: -96.2%
Qual. Beats: 0
Rev. Trend: -94.9%
Qual. Beats: 0
Warnings
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
InMode Ltd. is an Israel-based medical technology company specializing in the design and manufacture of energy-based aesthetic devices. The company utilizes proprietary radio frequency (RF) technologies to offer minimally invasive, non-invasive, and hands-free solutions for body contouring, skin tightening, and women’s health. Its global distribution network spans North America, Europe, and Asia, targeting a diverse range of dermatological and gynecological procedures.
The medical aesthetics sector is characterized by high barriers to entry due to stringent regulatory approval processes for medical devices. InMode’s business model focuses on a razor-and-blade strategy, generating revenue through both initial equipment sales and recurring sales of disposable handpieces required for specific treatments. For more comprehensive data on these revenue streams, consider exploring the analysis tools on ValueRay.
InMode distinguishes itself through Radio Frequency Assisted Lipolysis (RFAL), a technology designed to bridge the gap between traditional plastic surgery and non-invasive treatments. By offering surgical-grade results with lower downtime, the company captures market share from both traditional surgical clinics and medical spas.
- High interest rates dampen consumer demand for elective minimally invasive aesthetic procedures
- Sales of high-margin consumable pins track total installed base utilization rates
- Geopolitical instability in Israel poses potential manufacturing and supply chain risks
- Expansion into non-core medical segments like ophthalmology and gynecology diversifies revenue
- Competitive pressure from traditional plastic surgery and alternative non-invasive energy devices
| Net Income: 87.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -5.23 > 1.0 |
| NWC/Revenue: 161.1% < 20% (prev 143.2%; Δ 17.86% < -1%) |
| CFO/TA 0.12 > 3% & CFO 91.8m > Net Income 87.2m |
| Net Debt (-532.3m) to EBITDA (102.9m): -5.17 < 3 |
| Current Ratio: 8.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.9m) vs 12m ago -7.91% < -2% |
| Gross Margin: 77.84% > 18% (prev 80.03%; Δ -2.20% > 0.5%) |
| Asset Turnover: 51.48% > 50% (prev 55.68%; Δ -4.21% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.80 (Total Current Assets 680.8m - Total Current Liabilities 77.4m) / Total Assets 750.8m |
| B: 1.29 (Retained Earnings 968.5m / Total Assets 750.8m) |
| C: 0.14 (EBIT TTM 102.2m / Avg Total Assets 727.8m) |
| D: 7.38 (Book Value of Equity 661.3m / Total Liabilities 89.6m) |
| Altman-Z'' = 18.17 = AAA |
| DSRI: 0.74 (Receivables 40.7m/57.9m, Revenue 374.6m/392.4m) |
| GMI: 1.03 (GM 80.03% / 77.84%) |
| AQI: 0.94 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 0.95 (Revenue 374.6m / 392.4m) |
| TATA: -0.01 (NI 87.2m - CFO 91.8m) / TA 750.8m) |
| Beneish M = -3.29 (Cap -4..+1) = AA |
As of June 19, 2026, the stock is trading at USD 13.40 with a total of 517,747 shares traded.
Over the past week, the price has changed by -0.67%,
over one month by -4.96%,
over three months by -0.37% and
over the past year by +0.45%.
InMode has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold INMD.
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.3 | 6.9% |
P/E Trailing = 9.8963
P/E Forward = 9.901
P/S = 2.1685
P/B = 1.2801
P/EG = 2.9004
Revenue TTM = 374.6m USD
EBIT TTM = 102.2m USD
EBITDA TTM = 102.9m USD
Long Term Debt = unknown (none)
Short Term Debt = 3.22m USD (from shortTermDebt, last fiscal year)
Debt = 4.83m USD (from shortLongTermDebtTotal, last quarter) (leases 4.83m already included)
Net Debt = -532.3m USD (calculated: Debt 4.83m - CCE 537.2m)
Enterprise Value = 280.1m USD (812.4m + Debt 4.83m - CCE 537.2m)
Interest Coverage Ratio = unknown (Ebit TTM 102.2m / Interest Expense TTM 0.0)
EV/FCF = 3.09x (Enterprise Value 280.1m / FCF TTM 90.6m)
FCF Yield = 32.37% (FCF TTM 90.6m / Enterprise Value 280.1m)
FCF Margin = 24.20% (FCF TTM 90.6m / Revenue TTM 374.6m)
Net Margin = 23.27% (Net Income TTM 87.2m / Revenue TTM 374.6m)
Gross Margin = 77.84% ((Revenue TTM 374.6m - Cost of Revenue TTM 83.0m) / Revenue TTM)
Gross Margin QoQ = 75.05% (prev 78.28%)
Tobins Q-Ratio = 0.37 (Enterprise Value 280.1m / Total Assets 750.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.83m)
Taxrate = 14.69% (15.0m / 102.2m)
NOPAT = 87.2m (EBIT 102.2m * (1 - 14.69%))
Current Ratio = 8.80 (Total Current Assets 680.8m / Total Current Liabilities 77.4m)
Debt / Equity = 0.01 (Debt 4.83m / totalStockholderEquity, last quarter 661.3m)
Debt / EBITDA = -5.17 (Net Debt -532.3m / EBITDA 102.9m)
Debt / FCF = -5.87 (Net Debt -532.3m / FCF TTM 90.6m)
Total Stockholder Equity = 656.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.98% (Net Income 87.2m / Total Assets 750.8m)
RoE = 13.28% (Net Income TTM 87.2m / Total Stockholder Equity 656.6m)
RoCE = 15.18% (EBIT 102.2m / Capital Employed (Total Assets 750.8m - Current Liab 77.4m))
RoIC = 13.25% (NOPAT 87.2m / Invested Capital 658.0m)
WACC = 8.75% (E(812.4m)/V(817.2m) * Re(8.80%) + D(4.83m)/V(817.2m) * Rd(0.0%) * (1-Tc(0.15)))
Discount Rate = 8.80% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -68.89 | Cagr: -12.27%
[DCF] Terminal Value 71.62% ; FCFF base≈103.2m ; Y1≈90.5m ; Y5≈73.1m
[DCF] Fair Price = 26.86 (EV 1.10b - Net Debt -532.3m = Equity 1.63b / Shares 60.8m; r=8.75% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -96.25 | EPS CAGR: -20.00% | SUE: -0.76 | # QB: 0
Revenue Correlation: -94.90 | Revenue CAGR: -11.68% | SUE: 0.34 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.33 | Chg30d=-11.24% | Revisions=-50% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.34 | Chg30d=-5.93% | Revisions=-43% | Analysts=5
EPS current Year (2026-12-31): EPS=1.32 | Chg30d=-8.53% | Revisions=-50% | GrowthEPS=-17.4% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=1.45 | Chg30d=-5.02% | Revisions=-43% | GrowthEPS=+10.0% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -50%